Travere Therapeutics (TVTX) to Release Earnings on Thursday

Travere Therapeutics (NASDAQ:TVTX) is expected to issue its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $147.6840 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Travere Therapeutics Trading Down 9.1%

Shares of TVTX stock opened at $27.82 on Tuesday. The stock has a market cap of $2.49 billion, a P/E ratio of -26.25, a price-to-earnings-growth ratio of 0.76 and a beta of 0.83. Travere Therapeutics has a 1 year low of $12.91 and a 1 year high of $42.13. The company has a current ratio of 2.75, a quick ratio of 2.71 and a debt-to-equity ratio of 4.23. The stock has a 50 day simple moving average of $33.13 and a 200 day simple moving average of $28.65.

Analyst Ratings Changes

A number of research firms have recently weighed in on TVTX. Piper Sandler upped their target price on Travere Therapeutics from $35.00 to $38.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Wall Street Zen raised shares of Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Zacks Research downgraded shares of Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th. Citigroup raised their target price on shares of Travere Therapeutics from $34.00 to $48.00 and gave the company a “buy” rating in a report on Friday, October 31st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Eleven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $38.62.

Insider Activity at Travere Therapeutics

In other news, CAO Sandra Calvin sold 4,333 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $32.12, for a total transaction of $139,175.96. Following the sale, the chief accounting officer directly owned 49,080 shares in the company, valued at approximately $1,576,449.60. The trade was a 8.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Christopher R. Cline sold 1,745 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $32.19, for a total value of $56,171.55. Following the completion of the transaction, the chief financial officer directly owned 111,226 shares of the company’s stock, valued at $3,580,364.94. This represents a 1.54% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 331,925 shares of company stock worth $11,318,755 over the last 90 days. 4.06% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Travere Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC increased its position in Travere Therapeutics by 179.2% during the 4th quarter. Squarepoint Ops LLC now owns 319,658 shares of the company’s stock valued at $12,214,000 after purchasing an additional 205,181 shares during the period. Verition Fund Management LLC bought a new stake in shares of Travere Therapeutics in the 4th quarter valued at $2,140,000. Mariner LLC increased its position in shares of Travere Therapeutics by 105.6% during the fourth quarter. Mariner LLC now owns 18,219 shares of the company’s stock worth $696,000 after buying an additional 9,359 shares during the period. Entropy Technologies LP increased its position in shares of Travere Therapeutics by 32.2% during the fourth quarter. Entropy Technologies LP now owns 22,201 shares of the company’s stock worth $848,000 after buying an additional 5,408 shares during the period. Finally, FORA Capital LLC bought a new position in Travere Therapeutics during the fourth quarter worth $307,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.